Flares of acute graft-versus-host disease : a Mount Sinai Acute GVHD International Consortium analysis
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.84; 95% confidence interval [CI], 3.19-7.36; P < .001). Flares were more severe (grades 3/4, 41% vs 16%; P < .001) and had more frequent lower gastrointestinal (LGI) involvement (55% vs 32%; P < .001) than the initial GVHD. At CR/VGPR, elevated MAGIC biomarkers predicted the future occurrence of a flare, along with its severity and LGI involvement. In multivariate analyses, higher Ann Arbor (AA) biomarker scores at CR/VGPR were significant risk factors for flares (AA2 vs AA1: aHR, 1.81 [95% CI, 1.32-2.48; P = .001]; AA3 vs AA1: aHR, 3.14 [95% CI, 1.98-4.98; P < .001]), as were early response to initial treatment (aHR, 1.84; 95% CI, 1.21-2.80; P = .004) and HLA-mismatched unrelated donor (aHR, 1.74; 95% CI, 1.00-3.02; P = .049). MAGIC biomarkers also stratified the risk of NRM both at CR/VGPR and at the time of flare. We conclude that GVHD flares are common and carry a significant mortality risk. The occurrence of future flares can be predicted by serum biomarkers that may serve to guide adjustment and discontinuation of immunosuppression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 8 vom: 23. Apr., Seite 2047-2057 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akahoshi, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 23.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023012091 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368139581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368139581 | ||
| 003 | DE-627 | ||
| 005 | 20240424231944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023012091 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM368139581 | ||
| 035 | |a (NLM)38324721 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akahoshi, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flares of acute graft-versus-host disease |b a Mount Sinai Acute GVHD International Consortium analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a ABSTRACT: The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.84; 95% confidence interval [CI], 3.19-7.36; P < .001). Flares were more severe (grades 3/4, 41% vs 16%; P < .001) and had more frequent lower gastrointestinal (LGI) involvement (55% vs 32%; P < .001) than the initial GVHD. At CR/VGPR, elevated MAGIC biomarkers predicted the future occurrence of a flare, along with its severity and LGI involvement. In multivariate analyses, higher Ann Arbor (AA) biomarker scores at CR/VGPR were significant risk factors for flares (AA2 vs AA1: aHR, 1.81 [95% CI, 1.32-2.48; P = .001]; AA3 vs AA1: aHR, 3.14 [95% CI, 1.98-4.98; P < .001]), as were early response to initial treatment (aHR, 1.84; 95% CI, 1.21-2.80; P = .004) and HLA-mismatched unrelated donor (aHR, 1.74; 95% CI, 1.00-3.02; P = .049). MAGIC biomarkers also stratified the risk of NRM both at CR/VGPR and at the time of flare. We conclude that GVHD flares are common and carry a significant mortality risk. The occurrence of future flares can be predicted by serum biomarkers that may serve to guide adjustment and discontinuation of immunosuppression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Spyrou, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Hoepting, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Aguayo-Hiraldo, Paibel |e verfasserin |4 aut | |
| 700 | 1 | |a Ayuk, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Chanswangphuwana, Chantiya |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Hannah K |e verfasserin |4 aut | |
| 700 | 1 | |a Eder, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Etra, Aaron M |e verfasserin |4 aut | |
| 700 | 1 | |a Grupp, Stephan A |e verfasserin |4 aut | |
| 700 | 1 | |a Hexner, Elizabeth O |e verfasserin |4 aut | |
| 700 | 1 | |a Hogan, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Kitko, Carrie L |e verfasserin |4 aut | |
| 700 | 1 | |a Kraus, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Al Malki, Monzr M |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Qayed, Muna |e verfasserin |4 aut | |
| 700 | 1 | |a Reshef, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Schechter, Tal |e verfasserin |4 aut | |
| 700 | 1 | |a Ullrich, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Vasova, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Wölfl, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Zeiser, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Baez, Janna |e verfasserin |4 aut | |
| 700 | 1 | |a Beheshti, Rahnuma |e verfasserin |4 aut | |
| 700 | 1 | |a Eng, Gilbert |e verfasserin |4 aut | |
| 700 | 1 | |a Gleich, Sigrun |e verfasserin |4 aut | |
| 700 | 1 | |a Kasikis, Stelios |e verfasserin |4 aut | |
| 700 | 1 | |a Katsivelos, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalyk, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, George |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a DeFilipp, Zachariah |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, James L M |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, John E |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Ryotaro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 8 vom: 23. Apr., Seite 2047-2057 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:8 |g day:23 |g month:04 |g pages:2047-2057 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023012091 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 8 |b 23 |c 04 |h 2047-2057 | ||